CY1106839T1 - Διαδικασια για παραγωγη της β-μορφης κρυσταλλου νατεγλινιδις - Google Patents

Διαδικασια για παραγωγη της β-μορφης κρυσταλλου νατεγλινιδις

Info

Publication number
CY1106839T1
CY1106839T1 CY20071101136T CY071101136T CY1106839T1 CY 1106839 T1 CY1106839 T1 CY 1106839T1 CY 20071101136 T CY20071101136 T CY 20071101136T CY 071101136 T CY071101136 T CY 071101136T CY 1106839 T1 CY1106839 T1 CY 1106839T1
Authority
CY
Cyprus
Prior art keywords
crystals
crystal
nateglinide
type
nateglinidis
Prior art date
Application number
CY20071101136T
Other languages
English (en)
Inventor
Michito Sumikawa
Makoto Maruo
Kazuo Miyazaki
Shigehiro Nishina
Yukiko Matsuzawa
Original Assignee
Ajinomoto Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co., Inc. filed Critical Ajinomoto Co., Inc.
Publication of CY1106839T1 publication Critical patent/CY1106839T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Μια μέθοδος παρέχεται για παραγωγή κρυστάλλων τύπου-Β της νατεγλινίδης ουσιαστικά χωρίς κρυστάλλους τύπου-Η, η οποία περιλαμβάνει την ξήρανση διαλυτωμένων υγρών κρυστάλλων της νατεγλινίδης σε μια χαμηλή θερμοκρασία έως ότου δεν παραμένει καθόλου διαλύτης και την διεξαγωγή μιας μετατροπής κρυστάλλων της. Σύμφωνα με αυτήν τη μέθοδο, κρύσταλλοι τύπου-Β της νατεγλινίδης μπορούν να παραχθούν σε μια βιομηχανική κλίμακα χωρίς να επιτρέπεται σε άλλες μορφές του κρυσταλλικού πολυμορφισμού να συνυπάρχουν.
CY20071101136T 2000-10-24 2007-08-28 Διαδικασια για παραγωγη της β-μορφης κρυσταλλου νατεγλινιδις CY1106839T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000324375 2000-10-24
PCT/JP2001/009293 WO2002034713A1 (fr) 2000-10-24 2001-10-23 Procede de production de cristaux de nateglinide a forme b

Publications (1)

Publication Number Publication Date
CY1106839T1 true CY1106839T1 (el) 2012-05-23

Family

ID=18801920

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101136T CY1106839T1 (el) 2000-10-24 2007-08-28 Διαδικασια για παραγωγη της β-μορφης κρυσταλλου νατεγλινιδις

Country Status (18)

Country Link
US (2) US20030229249A1 (el)
EP (1) EP1334964B1 (el)
JP (1) JP4225057B2 (el)
KR (1) KR100810930B1 (el)
CN (1) CN100422143C (el)
AT (1) ATE370115T1 (el)
AU (1) AU2001296001A1 (el)
BR (1) BR0114846A (el)
CA (1) CA2426745C (el)
CY (1) CY1106839T1 (el)
DE (1) DE60130014T2 (el)
DK (1) DK1334964T3 (el)
ES (1) ES2288997T3 (el)
MX (1) MXPA03003575A (el)
PT (1) PT1334964E (el)
RU (1) RU2275354C2 (el)
TW (1) TWI293290B (el)
WO (1) WO2002034713A1 (el)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1283054A4 (en) * 2000-03-17 2006-04-12 Ajinomoto Kk MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
PT1334963E (pt) * 2000-10-18 2007-09-20 Ajinomoto Kk Processo para a produção de cristais de nateglinida
CN1273442C (zh) * 2000-10-18 2006-09-06 味之素株式会社 酰基苯丙氨酸的制备方法
WO2002040010A1 (fr) * 2000-10-24 2002-05-23 Ajinomoto Co.,Inc. Preparations de medicament contenant du nateglinide
RU2271805C2 (ru) * 2000-10-24 2006-03-20 Адзиномото Ко., Инк. Препарат, содержащий натеглинид
AU2003236243A1 (en) * 2002-04-15 2003-10-27 Ajinomoto Co., Inc. Novel nateglinide crystal
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
AU2003253971A1 (en) * 2002-07-18 2004-02-09 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
ATE349418T1 (de) * 2003-11-26 2007-01-15 A M S A Anonima Materie Sint E Verfahren zur herstellung von nateglinidin der b- form
EP1656339A1 (en) * 2004-05-07 2006-05-17 Teva Pharmaceutical Industries Ltd Polymorphic forms of nateglinide
WO2005110395A1 (en) * 2004-05-19 2005-11-24 University Of South Carolina System and device for magnetic drug targeting with magnetic drug carrier particles
US20080096970A1 (en) * 2004-05-20 2008-04-24 Sundaram Venkataraman Stable Nateglinide Form B Compositions
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
KR100837843B1 (ko) * 2006-12-26 2008-06-13 씨제이제일제당 (주) 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물
CA2802455A1 (en) 2010-06-14 2011-12-22 Cipla Limited A process for the preparation of nateglinide
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
AU2013257708A1 (en) * 2012-05-08 2014-12-04 Cellixbio Private Limited Compositions and methods for the treatment of diabetes
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
CN104583182A (zh) 2012-05-23 2015-04-29 塞利克斯比奥私人有限公司 用于治疗粘膜炎的组合物和方法
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
CN104402756B (zh) * 2014-11-27 2016-08-31 天方药业有限公司 一种高纯度那格列奈的制备方法
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
JP6679616B2 (ja) 2015-01-06 2020-04-22 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 炎症及び疼痛の治療のための組成物及び方法
CN109369443A (zh) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 一种新的那格列奈h晶型的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
DE10199058I2 (de) 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
ES2257772T3 (es) * 1996-11-15 2006-08-01 Ajinomoto Co., Inc. Preparacion de nateglinida en comprimidos.
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
RU2002120498A (ru) * 1999-12-28 2004-04-10 Адзиномото Ко., Инк. (Jp) Противодиабетический препарат для перорального введения
EP1283054A4 (en) * 2000-03-17 2006-04-12 Ajinomoto Kk MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
CN1273442C (zh) * 2000-10-18 2006-09-06 味之素株式会社 酰基苯丙氨酸的制备方法
PT1334963E (pt) * 2000-10-18 2007-09-20 Ajinomoto Kk Processo para a produção de cristais de nateglinida
RU2271805C2 (ru) * 2000-10-24 2006-03-20 Адзиномото Ко., Инк. Препарат, содержащий натеглинид
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Also Published As

Publication number Publication date
DE60130014D1 (de) 2007-09-27
WO2002034713A1 (fr) 2002-05-02
EP1334964B1 (en) 2007-08-15
CN100422143C (zh) 2008-10-01
CA2426745C (en) 2009-09-15
EP1334964A1 (en) 2003-08-13
TWI293290B (el) 2008-02-11
US7544834B2 (en) 2009-06-09
ES2288997T3 (es) 2008-02-01
US20070232829A1 (en) 2007-10-04
JPWO2002034713A1 (ja) 2004-03-04
BR0114846A (pt) 2004-02-25
JP4225057B2 (ja) 2009-02-18
PT1334964E (pt) 2007-09-20
DE60130014T2 (de) 2008-05-08
KR100810930B1 (ko) 2008-03-10
ATE370115T1 (de) 2007-09-15
CN1483018A (zh) 2004-03-17
EP1334964A4 (en) 2005-09-28
MXPA03003575A (es) 2003-07-14
US20030229249A1 (en) 2003-12-11
CA2426745A1 (en) 2003-04-23
KR20030059212A (ko) 2003-07-07
RU2275354C2 (ru) 2006-04-27
AU2001296001A1 (en) 2002-05-06
DK1334964T3 (da) 2007-09-24

Similar Documents

Publication Publication Date Title
CY1106839T1 (el) Διαδικασια για παραγωγη της β-μορφης κρυσταλλου νατεγλινιδις
SG125214A1 (en) Method of low temperature imprinting process with high pattern transfer yield
CY1114351T1 (el) Παραγωγα ν-φαινυλ-2-πυριμιδινης-αμινης
TWI319210B (en) Semiconductor device structures and methods of forming semiconductor structures
BR0008050A (pt) Processo e dispositivo para filtração emcontracorrente
TW200632593A (en) Lithographic rinse solution and resist-pattern forming method using the same
DK1720823T3 (da) Ny fremgangsmåde til syntese af substituerede alpha-amino-indanderivater
ITMI20021737A1 (it) Processo di purificazione di nanotubi di carbonio.
BR0213561B1 (pt) processo para a preparaÇço de amidas de Ácido 2-halopiridincarboxÍlico.
EA200301292A1 (ru) Способ синтеза тропенола для его получения в промышленном масштабе
ATE265416T1 (de) Kontinuierliches adiabatisches verfahren zur herstellung von nitrochlorbenzol
DK1458764T3 (da) Fremgangsmåde til fremstilling og fraktionering af gelatinerede og ikke-gelatinerede carrageenaner fra tokomponenttang
FR2843749B1 (fr) Procede de fabrication de pentafluoroethane
RU2008138015A (ru) Способ получения n-(1-адамантил)ацетамида
CL2004001052A1 (es) Proceso para preparar modafinil de granulometria definida a partir de dmsam y amoniaco a una temperatura y agitacion predeterminada.
HUP0102124A2 (hu) Eljárás 2-acetiltio-3-fenil-propionsav és sói előállítására
DK1493734T3 (da) Ny krystalform af 5-hydroxy-1-methylhydantoin
BR0115224A (pt) Processo para a peparação de ácido acético
NO20075375L (no) Framgangsmate for stripping
FR2894250B1 (fr) Procede de fabrication du pentafluoroethane
HUP0303819A2 (hu) Egylépéses eljárás toluolszármazékok előállítására
ATE368242T1 (de) Lithographisches verfahren zur herstellung von mikrobauteilen
DE50205226D1 (de) Verfahren zur herstellung von vanillylamin hydrochlorid
BR0108622A (pt) Processo para a n-formilação seletiva de n-hidroxil aminas
BR0200325B1 (pt) processo de obtenÇço de Ácido tereftÁlico por meio de reciclagem quÍmica de pet.